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Anti-myeloperoxidase antibodies stimulate neutrophils to
damage human endothelial cells
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Anti-myeloperoxidase antibodies stimulate neutrophils to damage hu-
man endothelial cells. Anti-myeloperoxidase autoantibodies are found in
association with idiopathic necrotizing glomerulonephritis and systemic
vasculitis. It is not known if their presence is an epiphenomen or an
integral part of the pathogenic process. To further delineate their
hypothesized pathogenicity, we studied their ability to stimulate neu-
trophils to damage human umbilical vein endothelial cells in vitro.
Anti-myeloperoxidase antibodies from human, rabbit and mouse
sources were utilized. These antibodies stimulated neutrophils to dam-
age endothelial cells as determined by 51Cr release. The effect was
dependent on priming the neutrophils with tumor necrosis factor-a, and
further enhanced with the addition of endotoxin. The amount of
endothelial cell damage was dependent on the dose of anti-myeloper-
oxidase, the source of the neutrophils, the concentration of TNF, and
the presence of endotoxin. Under identical conditions, control antibod-
ies did not stimulate neutrophils to damage endothelial cells. The effect
was confirmed by labeling the endothelial cells with 3H-adenine which
yielded the same results. These results provide further in vitro evidence
that anti-myeloperoxidase autoantibodies may play a significant role in
the pathogenesis of idiopathic pauci-immune glomerulonephritis and
vasculitis.
Anti-neutrophil cytoplasmic antibodies (ANCA) are autoanti-
bodies directed against constituents of the primary granules of
polymorphonuclear leucocytes (PMN) and lysosomes of mono-
cytes. They are found in the sera of patients with pauci-immune
necrotizing glomerulonephritis and systemic vasculitis, includ-
ing Wegener's granulomatosis and polyarteritis nodosa [1].
ANCA that produce an artifactual perinuclear staining by
indirect immunofluorescence microscopy on alcohol-fixed
PMN (P-ANCA) are usually specific for myeloperoxidase
(MPO) [2]. Most ANCA that produce a cytoplasmic pattern by
indirect immunofluorescence (C-ANCA) are directed against
proteinase 3 [3].
The finding of an autoantibody directed against one of the
main cells involved in the acute phase of the immune response
has led to the hypothesis that ANCA play a pathogenic role in
glomerular and vascular inflammation. The potential pathogenic
function of ANCA has been supported by the finding that these
autoantibodies stimulate PMN in vitro to degranulate and
produce reactive oxygen species [4]. In this study, we investi-
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gated whether anti-myeloperoxidase (aMPO) antibodies could
stimulate PMN to injure human endothelial cells in vitro.
Methods
Isolation of endothelial cells
Human endothelial cells (HUVEC) were isolated from um-
bilical cord veins by collagenase (Sigma Chemical Co., St.
Louis, Missouri, USA) digestion based on Gimbrone's method
[5]. They were cultured in RPMI-1640 with 20% HI fetal calf
serum, 50 p.g/ml gentamicin, 200 tg/ml kanamycin, 90 g/ml
heparin (Sigma) and 4.0 ng/ml acidic fibroblast growth factor (R
& D Systems, Minneapolis, Minnesota, USA). The cells were
grown to near confluence in tissue culture dishes that had been
coated with 1% gelatin (Sigma) and then passed with trypsin
0.05%/EDTA 0.02% into 48 well plates (Costar, Cambridge,
Massachusetts, USA) for the injury assay. All cells were used
at the second or third passage. Endothelial cell phenotype was
confirmed by typical cobblestone morphology and the presence
of von Willebrand's factor antigen using rabbit anti-human vWF
(DAKO, Carpinteria, California, USA). All effects were ob-
served in wells that were 100% confluent. The density of the
endothelial cells was 100,000 cells/well.
Isolation of polymorphonuclear leucocytes
Human PMN were obtained from normal human donors.
Fifty milliliters of whole blood was drawn into a heparinized
syringe and the RBCs sedimented with "Plasmagel" (Cellular
Products, Buffalo, New York, USA). The PMN were separated
with a Ficoll-Hypaque gradient (Sigma) and the remaining
RBCs removed with hypotonic lysis.
Antibodies
Plasma was obtained from patients who had undergone
plasmapheresis as part of the treatment of their disease. The
diagnoses of the patients were MPO-ANCA associated pauci-
immune necrotizing vasculitis and ANCA (—) necrotizing gb-
merulonephritis. The plasma was used at a dilution of 1:7.
Patient IgG was prepared by DEAE-Sephacel (Sigma) anion
absorption of plasma followed by precipitation of the superna-
tant with 50% ammonium sulfate. The samples were dialyzed
against PBS overnight. The two samples were prepared in
parallel and had similar LPS concentrations of less than 120
pglml. The final concentration of the IgG in the injury assay
ranged from 0.5 mg/mI to 2.0 mg/mI. We have previously
demonstrated that heterologous antibodies against azurophiic
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granule constituents activate PMN in vitro in a totally analo-
gous fashion to PMN activation by ANCA [4, 61. Therefore in
the experiments described below, both autoantibodies (that is,
ANCA) and heterologous antibodies specific for MPO were
tested as well as negative control antibodies. Mouse mono-
clonal anti-human MPO, rabbit polyclonal anti-human MPO
(R-aMPO), anti-human placental alkaline phosphatase, and
anti-human lysozyme were obtained from DAKO. If not other-
wise stated, the final concentration of the R-aMPO was 50
g/ml.
Stimulators
Recombinant human TNF-a was obtained from Genzyme
(Boston, Massachusetts, USA). The biologic activity was 50
pg/U as determined by killing of actinomycin D treated murine
L929 cells. Endotoxin from E. coli 026:B6 was purchased from
Dilco (Detroit, Michigan, USA). If not otherwise stated, the
concentration of TNF-a was 50 U/mI and of LPS was 500ng/ml.
In the LPS dose response experiment, the concentrations used
were 0.5, 1.0, 2.5, 5.0, 7.5, and 10.0 pg/ml.
Injury assay
All conditions were run in duplicate using the same HUVEC
source and passage, and the same PMN donor in control and
experimental conditions unless otherwise stated. Only HUVEC
that were in media that contained <0.01 ng/ml endotoxin
(QCL-1000 LAL kit, Whitaker Bioproducts, Walkersville,
Maryland, USA) were utilized. HUVEC were radiolabeled with
15 Ci/ml 51Cr (NEN, Boston, Massachusetts, USA) overnight
in the 48-well plate and incubated with 300 U/mi TNF-a for
three hours in order to prime the endothelial cells [71. The
monolayers were then washed and the experiment performed in
RPMI-1640 with 1% HI FCS. At time zero the antibodies plus
TNF and/or LPS were added with the PMN. The final concen-
tration of the PMN was 2.0 x 106/ml. The final well volume was
750 p1. The wells were sampled over six hours and the sample
volume replaced at each time point with media. The sample
volumes of 150 p1 were withdrawn from the top of the media so
as not to disturb the endothelial monolayer.
The 5tCr CPM were determined on an LKB gamma counter
(Model 1272). At the end of the experiment, the cells were lysed
with 10 N NaOH and the post-lysis 51Cr CPM measured. These
results were expressed as a fraction of the post-lysis radioac-
tivity. The 51Cr release at each time point and the post-lysis was
adjusted for the amount present at time = 0, the volume of the
well, and the amount previously removed. A representative
sample of the 51Cr CPM released is presented in Table 1. To
confirm that the 51Cr release was due to lysis and not detach-
ment in two experiments the samples were centrifuged at 400 X
g for 10 minutes. The differences in 51Cr release between the
various conditions were found only in the supernatant and not
in the pellet fractions.
To further substantiate the ability of aMPO to stimulate
primed PMN to damage HUVEC, the more sensitive indicator
of injury, 3H-adenine (NEN), was substituted for 51Cr as the
marker of endothelial cell damage [81. The HUVEC were
incubated for 16 hours with 5 CiIml 3H-adenine. They were
then handled in an identical manner to the 51Cr protocol. The
amount of 3H-adenine released was measured in a liquid scm-
Table 1. Representative CPM from duplicate samples
Time Total CPM in well
(HR) a-Alk phos R-aMPO M-aMPO
1871 2047 1978 1242 1932 1855
2 1659 2046 3440 2364 1916 2657
3 4395 4906 7707 8409 14974 11855
4 6816 6089 13446 12264 24589 23603
5 7945 8537 16814 15494 34495 32744
6 10064 11327 18568 16723 37757 38102
Post-lysis 60813 56088 59914 57051 64622 66480
Duplicate results of 51Cr released from HUVEC injured by PMN
stimulated by control and experimental antibodies. The PMN were
stimulated with 10 tg/ml mouse monoclonal anti-human myeloperox-
idase (M-aMPO), 50 g/ml rabbit polyclonal anti-human alkaline phos-
phatase (a-Alk phos), or 50 g/ml rabbit polyclonal anti-human my-
eloperoxidase (R-aMPO) in the presence of 50 U/ml TNF-a and 500
ng/ml LPS. The CPM have been adjusted for background, T = 0 CPM,
amount of 51Cr previously removed from the well, and the assay volume
removed.
tillation counter (Packard Instrument Co., Downers Grove,
Illinois, USA; Model #4530).
The LDH concentration was determined as previously de-
scribed [9]. LDH activity was measured in an enzymatic test
where NAD is reduced by the conversion of lactate to
pyruvate. The NADH then reduces FAD which in turn
reduces the tetrazolium dye INT, resulting in a formazan that is
measured spectrophotometrically at 490 nm.
Day to day variability in the amount of 51Cr release was
observed. On certain days, regardless of the stimulator em-
ployed no signal could be detected above the spontaneous
release. Both technical and biological causes of this phenome-
non were investigated.
Adding 100 ng/ml cold chromium to the assay media signifi-
cantly increased the amount of 51Cr detected from experimental
wells but not control wells. Since PMN also take up 51Cr [10],
this technique probably decreased the PMN uptake of 51Cr.
To determine if the periodic unresponsiveness was specific
for our stimulus the known stimulator of PMN-mediated HUVEC
damage, phorbyl myristate acetate (PMA) [11], was evaluated.
In six experiments 100% concordance was observed between
the ability of PMA (100 ng/ml) and aMPO antibodies to stimu-
late PMN to injure endothelial cells. Whether or not the entire
assay worked on a given day was independent of the stimulus.
To elucidate the variability attributable to the PMN, six
normal donors were evaluated. The PMN were isolated simul-
taneously and the assay was performed with identical reagents
on HUVEC derived from the same umbilical cord.
The rate of release of 51Cr, 3H-adenine, and LDH under
various conditions was compared using a multivariant linear
regression model, and expressed as the slope the standard
error. Wilcoxon rank sum test was used for comparison of
nonparametric data. The statistics were calculated with the
SAS System (SAS Institute, Inc., Cary, North Carolina, USA).
The "N" values represent the number of experiments in which
the effect was observed. The figures are from individual exper-
iments that are representative of the aggregate. Experiments
were excluded from analysis when the positive control values
were not above spontaneous release levels (for example, as
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shown above, when PMA failed to stimulate neutrophil medi-
ated endothelial cell damage).
Anti-endothelial cell antibodies
The direct cytotoxic potential of the antibodies on HUVEC
was determined with a complement dependent cytotoxicity
assay. Using a modification of the method of Leung et al [121,
patient plasma, R-ciMPO, and mouse monoclonal csMPO were
evaluated. 51Cr labeled HUVEC were incubated with the anti-,
bodies diluted in Hank's balanced salt solution with 1% BSA for
one hour at 37°C. After washing, the cells were incubated for
one hour with a 1:10 dilution of baby rabbit complement (Gibco,
Grand Island, New York, USA). The supernatent and post-lysis
51Cr CPM were determined and the results expressed as a
fraction of the post-lysis CPM. The anti-HLA-A,B monoclonal
antibody W6 (Accurate Chemical & Scientific Corp., Westbury,
New York, USA) was used as a positive control.
Results
Effect of patient plasma and IgG on 51Cr release
Plasma containing MPO-ANCA stimulated TNF-a and LPS
primed PMN to damage endothelial cells. The slope of 51Cr
release from the wells with ANCA (+) plasma was 0.072
0.008 versus 0.009 0.008 for ANCA (—) wells (P < 0.0001). At
the end of four hours 23% of available 51Cr was released from
the ANCA (+) wells versus 6% from the ANCA (—) wells.
The PMN stimulating activity was found to reside in the IgG
fraction of the plasma. At a concentration of 1 mg/mI MPO-
ANCA IgG added to the PMN with TNF-a and LPS resulted in
significantly more 51Cr release (P < 0.0001) than the samples
with IgG from disease controls (N = 3; Fig. 1). A linear dose
response effect was observed between 0.5 mglml and 2.0 mg/mI
IgG (r2 = 0.99). This phenomenon was further characterized
using heterologous polyclonal and monoclonal ctMPO.
Effects of csMPO, TNF-a, and LPS on 51Cr release
The combination of rabbit polyclonal aMPO (R-aMPO),
TNF-a and LPS resulted in a significant increase in PMN-
mediated 51Cr release from the endothelial cells when compared
with TNF-a and LPS without R-aMPO (N = 14; P < 0.0001;
Fig. 2). A dose response effect was observed with the R-aMPO
at concentrations of 25 and 50 tg/ml in combination with
TNF-a and LPS (Fig. 3). The effect was entirely dependent on
priming the PMN. Addition of 25 g/ml or 50 sg/ml of R-aMPO
without other stimulators did not significantly increase the rate
of 51Cr release over PMN alone (N = 2, P > 0.05).
TNF-a alone did not significantly increase 51Cr release over
PMN alone (P > 0.05, N = 9). In combination with R-aMPO,
TNF-a produced variable results that were in part concentra-
tion dependent. A total of 200 U/ml TNF-cs plus R-csMPO
resulted in a significant increase in PMN-mediated 5tCr release
when compared to R-cvMPO alone (P = 0.0003) or TNF-a alone
(P 0.02; Fig. 4). When the dose was lowered to 50 U/mI
inconsistent results were observed. In three experiments, a
significant increase in release was seen with the addition of
R-aMPO (P <0.05). However, in one there was a significant
decrease (P < 0.0001).
Consistent with published reports, the effect of LPS alone on
PMN-mediated 51Cr release from HUVEC was variable [13,
0.00
0 1 2 3
Time, hours
Fig. 1. Effect of purified patient IgG on PMN injury of HUVEC. Both
contain TNF and LPS; (0)1.0 mg/mI IgG from ANCA (+) patient(slope = 0.057 0.002); (LI) 1.0 mg/mI IgG from patient with n-GBM
glomerulonephritis [ANCA (—)] (slope = 0.031 0.002). (0 vs. LI: P <
0.0001).
14]. A significant increase in 51Cr release (P = 0.011) over PMN
alone was seen in one experiment but not in another. When
multiple concentrations of LPS ranging from 0.5 to 10.0 ig/ml
were evaluated in the absence of R-aMPO significant increases
in 51Cr release were seen with 2.5 g/ml and 10.0 g/ml (P <
0.03) but not with 0.5, 1.0, 5.0 or 7.5 g/m1. In studies with
R-aMPO in combination with LPS the 51Cr slope was not
significantly increased over PMN alone (N = 8). Thus LPS is
not a sufficient primer of PMN to facilitate aMPO stimulated
endothelial damage. However, when combined with TNF-a it
functioned in a synergistic manner to increase aMPO-stimu-
lated PMN-mediated endothelial damage. R-csMPO and TNF
produced a slope of 5tCr release of 0.029 0.005; with the
addition of LPS the slope increased to 0.073 0.004 (P <
0.0001).
The effect of mouse monoclonal aMPO was of particular
interest because it reacts in an identical manner as MPO-ANCA
on Western blot analysis [15]. Ten sg/ml of mouse monoclonal
ciMPO with TNF-a and LPS stimulated PMN to damage
HUVEC (N = 2). This effect was greater than that observed
with R-csMPO (P < 0.0001; Fig. 5).
Under identical conditions, control antibodies did not incite
PMN to damage endothelial cells. Rabbit polyclonal anti-
alkaline phosphatase did not increase the 51Cr release over the
TNF-a and LPS alone (N = 4, P > 0.05). The rate of 51Cr
release from TNF-a, LPS and anti-alkaline phosphatase was
significantly lower than the samples containing TNF-a, LPS
and R-aMPO (P = 0.03) or M-ciMPO (P < 0.0001; Fig. 5).
Rabbit anti-human lysozyme and anti-rat albumin produced
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Time, hours
Fig. 2. Effect of LPS and TNF priming on aMPO stimulated PMN
damage of HUVEC. Symbols are: (A) R-aMPO, TNF and LPS (slope
= 0.078 0.004); (X) LPS and TNF (slope = 0.028 0.004); (0)
R-aMPO (slope = 0.017 0.004). (A vs. X or 0: P <0.0001; X vs. 0:
P> 0.05).
similar results as the anti-alkaline phosphatase (data not
shown).
3H-adenine release is increased by anti-MPO antibodies
In order to test the system with another marker of endothelial
cell damage the release of 3H-adenine was investigated. The
effects of human MPO-IgG, R-aMPO, M-aMPO, and the neg-
ative control antibodies were confirmed in experiments where
the HUVEC were labeled with 3H-adenine. Significantly more
damage was produced by primed PMN stimulated with human
MPO-IgG versus disease control IgG (P = 0.001; Fig. 6). The
dose response effect of R-aMPO was again demonstrated at 25
and 50 jsg/ml (Fig. 7). As seen with 51Cr release the most
profound effect was seen with M-aMPO. The slope of 3H-
adenine release with M-aMPO plus the primers was 0.250
013, which resulted in 80% of the radiolabel being released at
four hours versus 22% for the primers alone (Fig. 7). The
addition of the negative control antibody, anti-alkaline phos-
phatase did not change the slope of 3H-adenine release corn-
pared to primers alone.
LDH release
LDH release was investigated as another measure of cell
injury, albeit less specific in that it can be released from either
HUVEC or PMN. Part of its utility was revealing PMN
autotoxicity when the LDH rose but the 51Cr did not. The
pattern of LDH release had some similarities to that seen with
51Cr release. R-aMPO did not significantly increase LDH over
PMN alone (N = 2,P> 0.05). TNF-a at concentrations from 10
to 200 U/mI also did not significantly increase LDH release (N
Time, hours
Fig. 3. Dose effect of R-aMPO. Symbols are: (D) 50 sg/ml R-aMPO,
TNF-a and LPS (slope = 0.078 0.004); (0)25 sg/ml R-aMPO, TNF-a
and LPS (slope = 0.052 0.004). (X) TNF-a and LPS (slope = 0.028
0.004). The slope of each line is significantly different from the other
two (P < 0.0001).
4, P > 0.05). However, the combination of TNF-a and
R-aMPO resulted in a slope that was significantly higher (N =
3; P < 0.0001) when compared to TNF-a or R-aMPO alone
(Fig. 8).
The pattern of LDH release differed from 51Cr release in
regards to the effect of LPS. LPS and R-aMPO resulted in a
significant increase in the LDH slope. Over the entire range of
LDH concentrations tested, LPS in combination with R-aMPO
resulted in a significantly higher LDH slope than R-aMPO or
LPS alone (P < 0.01). A dose response effect of LPS plus
R-aMPO was found. The slope of the sample containing 10.0
g/ml LPS (slope = 3.23 0.22) was significantly higher than
all samples containing 5.0 p.g/ml LPS (slope = 2.17 0.22; P
0.001) or less. The addition of higher concentrations of LPS
alone never produced the same effect as the addition of
R-aMPO.
Neutrophil donor variability
In order to evaluate the day to day variability in the assay
PMN from six donors were tested simultaneously on identical
HUVEC with TNF-a, LPS, and R-aMPO. As demonstrated in
Figure 9, there was a broad range of response from the six
donors when R-aMPO was added. When compared to the
donor specific control without R-aMPO, two of the donors'
PMN demonstrated a significant increase with R-aMPO (Table
2). With PMN from two of the non-responders, the slopes of
51Cr release with R-aMPO were not significantly different than
the others without R-aMPO. At t = 1 hour, the LDH concen-
trations from these two non-responders were significantly
a
0
U)
CI)
CI)0
a.
4.-0
C0
0
U-
0.50
0.40
0.30
0.20
0.10
0.00
a-0
U)
CI)>.
U)0
a.
0
C0
0
U-
0.50
0.40
0.30
0.20
0.10
0.00
0 1 2 3 4 5 6 0 1 2 3 4 5 6
Ewert et a!: Anti-MPO-stimulated PMN damage endothelial cells 379
Time, hours
Fig. 4. Effect of TNF-a priming on aMPO-induced PMN HUVEC
damage as measured by 51Cr release. Symbols are: (Li) 220 U/mi
TNF-a and R-aMPO (slope = 0.037 0.004); (0) 200 U/mi TNF-a
(slope = 0.025 0.004); (X) R-aMPO (slope = 0.017 0.004). (D vs.0: P = 0.02; [1 vs. X: P 0.0003; 0 vs. X: F> 0.05).
higher (P < 0.0001) than the four other donors using a Wilcoxon
rank sum test.
Since 51Cr is a more sensitive measure of HUVEC damage
[16] the LDH increase was attributed to PMN autotoxicity. The
hypothesis was tested that PMN overstimulation was the cause
of the PMN destruction without endothelial cell damage. The
PMN from one of the two non-responding donors were tested
with reduced amounts of TNF-a and LPS. Neither 10 nor 50
U/mi of TNF-a alone significantly increased 51Cr release over
untreated PMN. TNF-a and R-aMPO resulted in a significant
increase in the 51Cr release compared to untreated PMN (P =
0.0002) and PMN treated with TNF alone (P = 0.018). How-
ever, when 10 U/mI TNF-a and 100 ng!mi LPS were added
without R-aMPO a significant increase in 51Cr release was
observed (P = 0.009). Adding R-aMPO increased the slope
further, however, the slope was not significantly different than
that obtained with the TNF-a and LPS alone (P > 0.05).
Because these neutrophils were more sensitive to the synergis-
tic effect of LPS and TNF-a substantial HUVEC damage
occurred without R-aMPO. Therefore, the HUVEC damage
was not further increased upon the addition of R-aMPO. These
results confirmed that PMN from this donor were more sensi-
tive to the priming agents. The day to day variability seen in the
assay was at least in part attributable to the source of the PMN.
Anti-endothelial cell antibodies
If the MPO-ANCA plasma had cytotoxic anti-endothelial cell
antibodies, the increase in 51Cr release could be unrelated to
PMN activation by ANCA. In a complement mediated assay,
normal pooled sera released 6.7 1.5% (mean SD) of the
available 51Cr from unstimulated HUVEC and 7.8 2.0% from
Fig. 5. Effect of M-aMPO, R-aMPO, and the negative control anti-
body R-a-alkaline phosphatase on PMN injury of HUVEC. Symbols
are: (Lx) 10 g/ml M-aMPO, TNF-a and LPS (slope = 0.140 0.007);
(0) R-aMPO, TNF-n and LPS (slope = 0.064 0.007); (X) TNF-aand
LPS (slope = 0.041 0.007); (0) 50 tg/ml R-aalkaline phosphatase,
TNF-a and LPS (slope = 0.037 0.007). (L vs. 0, X, or Li: P < 0.0001;
o vs. X or Li: P < 0.03; X vs. 0: P> 0.05).
TNF-a stimulated HUVEC. The positive control anti-HLA
antibody caused a significant increase with both unstimulated
(32.2%; P < 0.0001) and stimulated HUVEC (35.8%; P <
0.0001) using a z test. MPO-ANCA released 7.6% of available
51Cr from the unstimulated HUVEC and 6.8% from the stimu-
lated HUVEC. These were not significantly different than
normal pooled sera (P > 0.05). R-aMPO and M-aMPO were
compared to buffer control. Without TNF-a stimulation of the
HUVEC, the percent release by buffer, R-aMPO, and
M-aMPO was 11.6%, 13.5%, and 8.2%, respectively; with
TNF-s stimulation it was 16.1%, 13.0% and 6.4%, respectively.
Thus it is unlikely that the damage to endothelial cells is a
consequence of direct antibody cytotoxicity.
Discussion
This study has demonstrated several new properties of
aMPO antibodies. In addition to activating PMN in vitro, they
are also capable of stimulating PMN to damage target cells.
Priming of the PMN is essential for endothelial cell damage to
occur. The amount of endothelial damage is dependent upon the
dose of aMPO present. The effect was demonstrated with
csMPO antibodies from four sources: 1) MPO-ANCA plasma, 2)
purified patient IgG, 3) rabbit polyclonal aMPO, and 4) mouse
monoclonal aMPO. Endothelial cell damage did not occur with
control antibodies.
The demonstration of ANCA-stimulated PMN-mediated
damage of HUVEC in vitro provides further evidence in
support of the hypothesized pathogenic role of these autoanti-
bodies. The association between these antibodies and vasculitis
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Fig. 6. Effect of purified patient JgG on PMN injury of HUVEC as
measured with 3H-adenine release. All contain TNF and LPS. Symbols
are:(0) 1.0mg/mi IgG from ANCA(+)patient(slope = 0.118 0.013),
(0)1.0 mg/mi IgG from patient with s-glomerular basement membrane
glomerulonephritis [ANCA (—)] (slope = 0.059 0.013). (0 vs. 0: P =
0.002).
was first made by Davies in 1982 [17]. We [181 and others [19]
have defined further the correlations between various ANCAs
and idiopathic glomerulonephritis. The first data that suggested
a pathogenic role for these autoantibodies were reported in
1990. We found that ANCA can stimulate cytokine primed and
to a lesser extent unprimed PMN to degranulate and produce
reactive oxygen species. Cytokine priming translocates the
intra-granular antigens to the cell surface, thereby making them
available to interact with ANCA [4]. These observations have
been extended by the demonstration that a range of heterolo-
gous antibodies directed against different constituents of the
primary granules also induce neutrophil activation [6]. Keogan
et al have also reported similar observations [20].
The current findings add further support to the contention
that ANCA are pathogenic. In order to support ANCA's
presumed role in causing vasculitis it was crucial to demon-
strate endothelial cell damage. It does not necessarily follow
that a substance that activates PMN will also stimulate them to
damage endothelial cells. Varani et al [21] found that immune
complexes, activated complement, and phorbol esters activated
PMN and stimulated them to damage endothelial cells. How-
ever, platelet activating factor and formyl-methionyl-leucyl-
phenylalanine (fMLP) while stimulating the production of reac-
tive oxygen species and protease release did not stimulate PMN
mediated endothelial cell injury. MPO-ANCA not only cause
neutrophil activation but also promote the more complex patho-
physiological phenomenon of endothelial cell injury.
ANCA and heterologous antibodies to MPO are an addition
to the list of agents that are able to stimulate PMN to injure
Time, hours
Fig. 7. Effect of M-aMPO and R-cxMPO on PMN injury of HUVEC as
measured with 3H-adenine release. All contain 10 U/mI TNF and 100
nglml LPS (A) 10 g/ml M-aMPO (slope = 0.250 0.013); (0)50 sg/ml
R-aMPO (slope = 0.194 0.013); (0)25 g/ml R-aMPO (slope = 0.111
0.013); (X) TNF and LPS (slope = 0.067 0.013). (A vs. 0 or X: P
<0.0001; A vs. El: P = 0.003; 0 vs. 0 orX: P< 0.0001; 0 vs. X: P <
0.02).
endothelial cells in vitro. C5a and immune complexes are the
only other physiologic factors identified that induce endothelial
damage by PMN [21, 22]. The known pharmacologic inciters of
PMN-mediated endothelial cell damage are fMLP [23] and PMA
[lii. Various groups have found conflicting results with C5a
[22, 24] and fMLP [25] in regards to their ability to stimulate
PMN-mediated endothelial cell injury. These differences are
probably attributable to contamination with LPS [23] and the
concentration of serum used in the assay [24]. It has previously
been demonstrated that LPS amplifies the effect of fMLP
stimulation of PMN [26] and increases their ability to damage
HUVEC [23]. Heterologous aMPO combined with TNF-a is
also a stimulator of PMN whose effect is enhanced by the
presence of LPS. However, in contrast to fMLP, LPS was not
necessary for the endothelial damage to occur, but its presence
amplified the effect.
There are interesting correlations between the clinical pre-
sentation of ANCA associated glomerulonephritis and this in
vitro system. In general ANCA titers correlate well with
disease activity, but some patients retain high titers despite
clinical quiescence [27]. Analogous to this, aMPO alone was
not found to be a sufficient stimulus for PMN to damage
endothelial cells in vitro. Priming factors, such as cytokines
with or without LPS, must be present. This priming depen-
dency of the system is probably due to the need for the
expression of PMN ANCA antigens [4] and adhesion molecules
[28, 29] on the PMN cell surface. Another clinical finding that
suggests the cytokine dependency of this disease in vivo is that
patients often experience a "viral prodrome" before the onset
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or exacerbation of nephritic symptoms [27]. Presumedly, in
vivo cytokine stimulation initiates translocation of PMN intra-
granular antigens thereby making them available to the ANCA
leading to PMN activation and vascular inflammation.
The variation seen between PMN from different donors may
also help explain the wide clinical spectrum of ANCA associ-
ated diseases. When primed PMN from six donors were eval-
uated simultaneously, three patterns of response were distin-
guished. PMN from two donors significantly increased HUVEC
damage when aMPO was added. Samples that contained PMN
from two of the four donors that did not demonstrate increased
HUVEC damage with aMPO had significantly higher LDH
concentrations after one hour of incubation with stimulators
without aMPO. We concluded that our usual concentrations
of primers resulted in PMN activation before attachment to
HUVEC and/or PMN autotoxicity. Either one of these events
would account for the absence of HUVEC damage.
Overstimulation of the PMN as the cause of the lack of
HUVEC damage was confirmed. PMN from one of these
donors were tested with decreased levels of primers and a
significant increase in HUVEC damage was demonstrated with
aMPO. Donor variability is not unique to this system, the effect
has been demonstrated previously with fMLP stimulated PMN
adherence to HUVEC [30]. These results demonstrate the
paradoxical nature of the HUVEC damage. The level of PMN
priming must be sufficient enough to translocate the intracellu-
lar ANCA antigens to the cell surface. However, if the PMN are
overstimulated, they either are able to injure HUVEC without
aMPO or die upon the addition of aMPO before injuring the
HUVEC.
The pronounced effect seen with the mouse monoclonal
Donor #
Slope of 51 release
% change P value(—)R-aMPO (+)R-aMPO
1 0.043 0.076 75.9 0.003
2 0.035 0.062 75.6 0.01
3 0.043 0.061 43.1 0.09
4 0.035 0.043 24.2 NS
5 0.040 0.049 22.7 NS
6 0.061 0.068 10.7 NS
Comparison of the slopes of 51Cr release from six donors evaluated
simultaneously. The PMN were primed with TNF-a and LPS. With #1
and #2 a significant increase in 51Cr release was observed with the
addition of R-aMPO. In contrast PMN from donors #4 and #5 with
R-aMPO resulted in 51Cr release that was not significantly different
from all cases without R-aMPO. The lack of a significant change was
due to inability to increase HUVEC damage over baseline. The slope
obtained with PMN without R-aMPO from donor #6 was not signifi-
cantly different than all of the cases with R-aMPO and was significantly
higher (P < 0.05) than #2, #4, and #5 without R-aMPO. The lack of a
significant increase was attributed to a high baseline 51Cr release.
aMPO is attributable to two factors. First, it would be expected
that the titer of specific aMPO antibodies would be substan-
tially higher than in the rabbit polyclonal or purified human
MPO-ANCA IgG preparations. Second, we have found that the
immunoreactivity of this monoclonal to MPO is identical to
MPO-ANCA [15]. In contrast, rabbit polyclonal aMPO reacts
with several MPO epitopes.
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Fig. 8. Effect of R-aMPO and TNF-a on LDH release. Symbols are:
(U) R-aMPO and 200 U/mI TNF-a (slope = 7.16 0.92); (X) R-aMPO
(slope 0.76 0.92); (0)200 U/mI TNF-a (slope = 0.31 0.92). (0 vs.
X or 0: P < 0.0001; X vs. 0: P> 0.05).
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Fig. 9. Donor variability in regards to response to aMPO. When six
donors were tested simultaneously the slope of the highest responder
was significantly greater (P < 0.01) than the slopes of the two lowest
responders. The response of the other three donors fell in between and
was not significantly different from any of the others.
Table 2. Detectable response to anti-myeloperoxidase is dependent
on the PMN donor
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There are several potential sources of bias in our experimen-
tal system. First, reagents may be contaminated with LPS. This
was controlled for through several means. When possible, as in
the case of tissue culture media, only reagents with <10 pg/mi
LPS were used. However, stimulating effects of LPS have been
reported at the 3 pg/mI level [261, which is below the detection
level of commercial assays. Thus we prepared reagents in
parallel with matched levels of LPS, as in the case of the patient
IgG preparations. There are also several findings that argue
against LPS being responsible for the effect observed with
aMPO. First, the degree of damage we report with aMPO
antibodies has never been observed by us or others [141 with
LPS as the sole stimulant. Second, the pattern of LDH release
was distinctly different between LPS and aMPO. At all con-
centrations tested, LPS never caused a significant increase in
LDH release. However, at the lowest LPS concentration
tested, addition of aMPO significantly increased LDH release.
A second source of potential bias with this experimental
system is anti-endothelial cell antibodies. Auto-antibodies di-
rected against endothelial cells have been found in patients with
Kawasaki' s disease [12], hemolytic uremic syndrome [311,
systemic lupus erythematosus [32], and other forms of vasculi-
tis [33] including Wegener's granulomatosus. We tested our
MPO-ANCA patient plasma for anti-endothelial cell antibodies
using a complement-mediated injury assay and found no cyto-
toxic activity when compared with normal serum or buffer.
In summary, these findings further support a role for MPO-
ANCA in the pathogenesis of pauci-immune glomerulonephritis
and vasculitis. They build on our previous report by demon-
strating that primed PMN activated by MPO-ANCA are able to
damage endothelial cells, which are a major site of injury in
ANCA-associated glomerulonephritis and vasculitis. The cy-
tokine dependency of this effect correlates with the clinical
finding that patients with ANCA may remain asymptomatic
until there is unrelated activation of the immune system as
occurs with viral infections. These results support the hypoth-
esis that ANCA cause idiopathic glomerulonephritis and vas-
culitis by activating primed PMN leading to tissue destruction.
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